Clinical Watch: May 2019

June 14, 2019

In this issue of Clinical Watch, we discuss the evolution of psoriasis treatment. We suggest criteria for a new biologic for plaque psoriasis and review the albumin-lowering effect of dapagliflozin. Finally, we review claims data to identify potential implications of a new psoriasis treatment.

For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacy solutions. 

Previous Flipbook
Clinical Watch: June 2019
Clinical Watch: June 2019

In this issue of Clinical Watch, we discuss the FDA guidance on biosimilar interchangeability.

Next Article
The FY 2020 Inpatient Prospective Payment System (IPPS) Proposed Rule from the perspective of Medicaid
The FY 2020 Inpatient Prospective Payment System (IPPS) Proposed Rule from the perspective of Medicaid

Annual updates that could impact Medicaid programs include labor and nonlabor shares of the wage area, wage...

Explore our Clinical Watch Newsletter

Learn More